J R Katz1, P Bareille, G Levitt, R Stanhope. 1. Department of Endocrinology, Great Ormond Street Hospital for Children, Great Ormond Street, London WC1N 3JH, UK.
Abstract
AIMS: To assess the impact of treatment for embryonal rhabdomyosarcoma on spinal growth and limb length and examine the response of these parameters to growth hormone (GH) treatment. METHODS: We conducted a retrospective case note review of 17 survivors of head and neck rhabdomyosarcoma followed up at a single institution. All children had been treated with chemotherapy and local radiotherapy. Growth velocity, height, sitting height, and subischial limb length SDS scores were analysed. RESULTS: Growth failure secondary to isolated GH deficiency (GHD) developed in 7/17 patients. GHD occurred at a median (range) of 3.4 (1.3-9.9) years after radiotherapy tumour doses of 46 (40-50) Gy. Growth velocity, height, and subischial limb length SDS were significantly reduced in the GHD group and improved with GH therapy. CONCLUSIONS: GH treatment resulted in a significant improvement in sitting height SDS. We discuss the unexpected improvement in spinal growth in survivors with GHD.
AIMS: To assess the impact of treatment for embryonal rhabdomyosarcoma on spinal growth and limb length and examine the response of these parameters to growth hormone (GH) treatment. METHODS: We conducted a retrospective case note review of 17 survivors of head and neck rhabdomyosarcoma followed up at a single institution. All children had been treated with chemotherapy and local radiotherapy. Growth velocity, height, sitting height, and subischial limb length SDS scores were analysed. RESULTS:Growth failure secondary to isolated GH deficiency (GHD) developed in 7/17 patients. GHD occurred at a median (range) of 3.4 (1.3-9.9) years after radiotherapy tumour doses of 46 (40-50) Gy. Growth velocity, height, and subischial limb length SDS were significantly reduced in the GHD group and improved with GH therapy. CONCLUSIONS: GH treatment resulted in a significant improvement in sitting height SDS. We discuss the unexpected improvement in spinal growth in survivors with GHD.
Authors: R B Raney; L Asmar; R Vassilopoulou-Sellin; M J Klein; S S Donaldson; J Green; R Heyn; M Wharam; A S Glicksman; E A Gehan; J Anderson; H M Maurer Journal: Med Pediatr Oncol Date: 1999-10
Authors: H Martelli; O Oberlin; A Rey; J Godzinski; R D Spicer; N Bouvet; C Haie-Meder; M J Terrier-Lacombe; J Sanchez de Toledo; D Spooner; D Sommelet; F Flamant; M C Stevens Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: Miro-Pekka Jussila; Tiina Remes; Julia Anttonen; Arja Harila-Saari; Jaakko Niinimäki; Tytti Pokka; Päivi Koskenkorva; Anna Sutela; Sanna Toiviainen-Salo; Pekka Arikoski; Pekka Riikonen; Mikko Arola; Päivi Lähteenmäki; Kirsti Sirkiä; Heikki Rantala; Maria Suo-Palosaari; Marja Ojaniemi Journal: PLoS One Date: 2018-12-18 Impact factor: 3.240